Novo NordiskSee all their emails

Novo Nordisk’s CagriSema 2.4 mg / 2.4 mg demonstrated significant reduction in HbA1c and weight across multiple studies in the REIMAGINE program presented at ADA 2026

A real announcement email from Novo Nordisk. Captured June 7, 2026.

Make this email yours

Migma AI designs one like it with your logo, colors, and images.

Novo Nordisk’s CagriSema 2.4 mg / 2.4 mg demonstrated significant reduction in HbA1c and weight across multiple studies in the REIMAGINE program presented at ADA 2026 email from Novo Nordisk screenshot

Captured Announcement

Press release announcement regarding Phase 3 clinical trial results for CagriSema in type 2 diabetes patients.

Standard corporate press release layout. Logo at the top, followed by bulleted highlights, then dense text blocks and multiple data tables. No clear CTA buttons. Minimal whitespace.

Original email and brand assets belong to their respective owners. Design notes describe the creative, not campaign results.